LXRX Lexicon Pharmaceuticals, Inc. - Common Stock
$2.45
मूल्य · अग 19, 2026
मौलिकता इस प्रकार है अग 6, 2026
52W रेंज
$1–$3
86% of range
विश्लेषक रेटिंग
BUY
11 analysts
मूल्य लक्ष्य
$4
+58% upside
P/E (TTM)
-17.5
ROE
-39.7%
शुद्ध लाभ मार्जिन
-101.1%
Lexicon Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
और पढ़ें
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company developing treatments for human disease. The company was founded in 1995 in The Woodlands, Texas under the name Lexicon Genetics, Incorporated by co-founders Professor Allan Bradley, FRS and Professor Bradley's postdoctoral fellow Arthur T Sands. The company has used its mouse gene knockout technology and in vivo screening capabilities to study nearly 5,000 genes in its Genome5000 program and has identified over 100 potential therapeutic targets. Lexicon has advanced multiple drug candidates into human clinical trials and has a broad and diverse pipeline of drug targets behind its clinical programs. Lexicon is pursuing drug targets in five therapeutic areas including oncology, gastroenterology, immunology, metabolism, and ophthalmology.
The company's clinical drug candidates include sotagliflozin (LX4211) for the treatment of type 2 diabetes; LX1033 for the treatment of irritable bowel syndrome and other gastrointestinal disorders; telotristat ethyl (LX1032) for the treatment of the symptoms associated with carcinoid syndrome; and LX2931 for the treatment of autoimmune diseases, such as rheumatoid arthritis.
Company history
Lexicon Pharmaceuticals was founded in September 1995 as a biotech venture of Baylor College of Medicine. The company went public in April 2000 with $220 million initial public offerings. In June, 2001 Lexicon purchased a privately owned small chemical library synthesis company, Coelacanth Corporation in Princeton, New Jersey, which became the site for the company's small molecule and medicinal chemistry efforts. The company's original name was Lexicon Genetics Incorporated, but in 2007, the name changed to Lexicon Pharmaceuticals, Inc. to reflect a renewed focus on drug development.
The company initially focused on using gene knockout technology to define the function of genes. This effort complemented and benefited from the international effort to sequence the human and mouse genomes (see Human Genome Project). Using its proprietary gene trapping and gene targeting technologies, the company created A repository of genetically modified mouse embryonic stem cells, known as OmniBank, and established a large-scale mammalian knockout program to discover the physiological and behavioral functions of the most druggable mammalian genes. The information collected from this program is stored in the company's LexVision database, which contains almost 5,000 gene knockouts studied. Over the years, Lexicon evolved from a genomics company into a drug discovery and development company focused on discovering and developing treatments for human disease. The company currently has multiple drug candidates in various stages of clinical trials.
In 2016, the company was ranked #8 on the Deloitte Fast 500 North America list.
Technology
Lexicon uses patented gene trapping and gene targeting technologies to generate and study knockout mice to discover the physiological and behavioral effects that result from the disruption of a single gene knockout. Because there is a close similarity in gene function and physiology between mice and humans, with a large majority of human genes having a counterpart in the mouse genome, knockout mouse technology has become a powerful tool in the discovery of new medicines.
The value of Lexicon's technology in drug discovery has been described in a retrospective analysis by the scientific journal Nature. The conclusion of this analysis was that, in most cases, there was a direct correlation when comparing the physiological characteristics, or phenotypes, of knockout mice to the therapeutic effect of the 100 best-selling drugs of 2001. The tremendous utility of knockout mouse technology was recognized in 2007 with the Nobel Prize in Physiology or Medicine to Drs. Mario Capecchi, Martin Evans, and Oliver Smithies.
In developing small molecule drugs for its validated targets, Lexicon uses medicinal chemistry known as "click chemistry." Dr. K. Barry Sharpless, who was awarded the 2001 Nobel Prize in Chemistry, developed this tools for the rapid synthesis of novel compounds. Lexicon uses solution-phase chemistry to generate diverse libraries of optically pure compounds that are built using organic reactions that allow the company to generate collections of diffrent compounds and to tailor the compound collections to address various therapeutic target families. Lexicon's medicinal chemists design these libraries by analyzing the chemical structures of drugs that have been proven safe and effective against human disease and using that knowledge in the design of scaffolds and chemical building blocks for the generation of large numbers of new drug-like compounds.
Locations
Lexicon operates from two locations found in Texas and New Jersey. The corporate headquarters are in The Woodlands, Texas just north of Houston. This location serves as Lexicon's primary research facility to discover and validate the company's drug targets and test drug candidates in preclinical research. The company's clinical development and regulatory team is also based at the corporate headquarters.
Lexicon's campus in Princeton, New Jersey is the home of Lexicon's small molecule medicinal chemistry and preclinical development efforts. This site serves as Lexicon's primary medicinal chemistry site to create new chemical entities for therapeutic development.
== References ==
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
LXRX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$2.44
मार्केट कैप
$894M
P/E (TTM)
-17.5
EPS (TTM)
$-0.14
राजस्व (TTM)
$50M
लाभांश प्रतिफल
—
ROE
-39.7%
D/E ऋण/इक्विटी
0.5
52W रेंज
$1 – $3
LXRX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
Configure
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व और शुद्ध आय
$50M
2016-12-31
→
2025-12-31
EPS
$-0.14
2017-12-31
→
2025-12-31
फ्री कैश फ्लो
$-68M
2016-12-31
→
2025-12-31
मार्जिन
-101.1%
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
मेट्रिक
5Y रुझान
LXRX
सहकर्मी माध्यिका
P/E (TTM)
-17.5
29.9
P/S (TTM)
18.0
14.4
P/B
8.3
4.4
EV / EBITDA
-17.6
—
Price / FCF (मूल्य / FCF)
-13.2
—
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
मेट्रिक
5Y रुझान
LXRX
सहकर्मी माध्यिका
Operating Margin (परिचालन मार्जिन)
-98.2%
—
Net Profit Margin (शुद्ध लाभ मार्जिन)
-101.1%
0.70%
ROA
-20.8%
-0.55%
ROE
-39.7%
-2.5%
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
मेट्रिक
5Y रुझान
LXRX
सहकर्मी माध्यिका
Debt / Equity (ऋण / इक्विटी)
0.5
—
Current Ratio (वर्तमान अनुपात)
4.9
3.9
Quick Ratio (त्वरित अनुपात)
4.7
—
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
मेट्रिक
5Y रुझान
LXRX
सहकर्मी माध्यिका
Revenue YoY (राजस्व YoY)
60.2%
—
Revenue CAGR 3Y (राजस्व CAGR 3Y)
610.2%
—
Revenue CAGR 5Y (राजस्व CAGR 5Y)
15.7%
—
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
मेट्रिक
5Y रुझान
LXRX
सहकर्मी माध्यिका
LXRX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
खरीदें
11 विश्लेषक
- मजबूत खरीद 3 27.3%
- खरीदें 5 45.5%
- होल्ड 3 27.3%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
5 विश्लेषक · 2026-08-19
मध्यिका
$3.10
माध्य
$3.86
अभी
$2.44
निम्न
$2.00
उच्च
$6.00
मध्यिका लक्ष्य
$3.10
+26.8%
माध्य लक्ष्य
$3.86
+57.7%
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
0.03%
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $-0.07 | $-0.05 | -0.02% |
| 31 मार्च 2026 | $0.00 | $-0.04 | 0.04% |
| 31 दिसमबर 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 सितमबर 2025 | $-0.04 | $-0.07 | 0.03% |
| 30 जून 2025 | $0.01 | $-0.08 | 0.09% |
| 31 मार्च 2025 | $-0.07 | $-0.10 | 0.03% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| LXRX | $421M | -8.2 | 60.2% | -101.1% | -39.7% | — |
| OMER | $1.23B | -343.6 | — | — | 1.9% | — |
| SPTX | — | — | — | — | — | — |
| PCRX | $1.06B | 161.8 | 3.6% | 0.97% | 0.97% | — |
| COLL | $1.47B | 26.8 | 23.6% | 8.1% | 23.5% | 59.4% |
| ACRS | $363M | -5.7 | -58.2% | -829.6% | -55.3% | — |
| SGP | — | — | — | — | 50.0% | — |
| AMPH | $1.22B | 13.2 | -1.7% | 13.6% | 12.7% | 49.5% |
| LLY | — | 46.8 | 44.7% | 31.7% | 101.2% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 16
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Cost of Revenue | $274.0K | $616.0K | $85.0K | $0 | $0 | $2M | $3M | $2M | $2M | $0 | $0 | · | |
| R&D Expense | $61M | $84M | $59M | $53M | $55M | $154M | $92M | $100M | $152M | $164M | $95M | $89M | |
| SG&A Expense | $37M | $143M | $114M | $48M | $32M | $47M | $57M | $64M | $66M | $43M | $24M | $19M | |
| Operating Expenses | $99M | $228M | $173M | $101M | $87M | $204M | $181M | $166M | $222M | $206M | $129M | $123M | |
| Operating Income | $-49M | $-197M | $-172M | $-101M | $-87M | $-48M | $141M | $-103M | $-131M | $-127M | $1M | $-100M | |
| Interest Expense | · | · | · | $3M | $802.0K | $15M | $21M | $21M | $7M | $7M | $7M | $2M | |
| Other Non-op | $7M | $12M | $8M | $2M | $134.0K | $3M | $3M | $4M | $2M | $2M | $572.0K | $2M | |
| Pretax Income | · | · | · | · | $-88M | $-59M | $124M | $-121M | $-136M | $-131M | $-5M | $-100M | |
| Income Tax | · | $0 | $0 | $0 | $0 | · | · | · | · | $0 | $0 | $-70.0K | |
| Net Income | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| EPS (Basic) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.23 | $-1.14 | $-1.17 | · | · | · | |
| EPS (Diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 | $-0.53 | $1.16 | $-1.14 | $-1.17 | · | · | · | |
| Shares (Basic) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | · | · | · | · | · | · | · | |
| Shares (Diluted) | 363,053,000 | 320,031,000 | 221,130,000 | 165,733,000 | 145,652,000 | 110,841,000 | 116,747,000 | 105,830,000 | 105,237,000 | · | · | · | |
| EBITDA | $-48M | $-197M | $-171M | $-100M | $-87M | $-45M | $145M | $-100M | $-133M | $-135M | · | $-98M |
बैलेंस शीट 30
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $34M | $67M | $22M | $46M | $64M | $126M | $36M | $80M | $62M | $47M | $203M | $137M | |
| Short-term Investments | $62M | $171M | $148M | $92M | $23M | $26M | $236M | $80M | $249M | $300M | $318M | $202M | |
| Receivables | $2M | $3M | $1M | $28.0K | $14.0K | $395.0K | $57M | $6M | $5M | $7M | $911.0K | $1M | |
| Inventory | $281.0K | $231.0K | $381.0K | $0 | · | $0 | $4M | $5M | $2M | $0 | · | · | |
| Other Current Assets | $3M | $5M | $5M | $2M | $2M | $5M | $5M | $3M | $4M | $4M | $10M | $5M | |
| Current Assets | $102M | $246M | $177M | $141M | $89M | $158M | $338M | $173M | $322M | $358M | $532M | $369M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $1M | $295.0K | $14M | $16M | $18M | $19M | $21M | $1M | |
| PP&E (Gross) | $5M | $5M | $7M | $6M | $6M | $6M | $76M | $76M | $76M | $79M | $81M | $37M | |
| Accum. Depreciation | $3M | $2M | $5M | $4M | $5M | $6M | $62M | $60M | $59M | $60M | $59M | $36M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | |
| Intangibles | · | · | · | · | · | · | $20M | $50M | $52M | $53M | $53M | $53M | |
| Other Non-current Assets | $368.0K | $368.0K | $828.0K | $412.0K | $2M | $1M | $2M | $285.0K | $429.0K | $461.0K | $433.0K | $3M | |
| Total Assets | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Accounts Payable | $3M | $15M | $14M | $10M | $9M | $5M | $12M | $12M | $39M | $53M | $20M | $13M | |
| Accrued Liabilities | $13M | $30M | $17M | $13M | $13M | $30M | $42M | $21M | $12M | $32M | $25M | $10M | |
| Current Liabilities | $21M | $45M | $32M | $23M | $22M | $47M | $65M | $37M | $105M | $165M | $123M | $45M | |
| Capital Leases | $7M | $5M | $5M | $5M | · | · | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | $0 | $6M | $6M | $19M | $19M | $19M | |
| Other Non-current Liabilities | $7M | $7M | $5M | $5M | $1M | $611.0K | $1M | $238.0K | $292.0K | $805.0K | $14M | $24M | |
| Total Liabilities | $77M | $152M | $136M | $77M | $23M | $47M | $301M | $311M | $368M | $318M | $366M | $187M | |
| Long-term Debt | $54M | $100M | · | $49M | $0 | $12M | $249M | $250M | $252M | $101M | $106M | $108M | |
| Total Debt | $54M | $100M | $100M | · | $0 | $12M | $245M | $245M | $246M | $101M | · | $108M | |
| Common Stock | $366.0K | $363.0K | $245.0K | $189.0K | $150.0K | $142.0K | $106.0K | $106.0K | $106.0K | $105.0K | $104.0K | $104.0K | |
| Paid-in Capital | $2.13B | $2.12B | $1.86B | $1.71B | $1.61B | $1.56B | $1.46B | $1.45B | $1.44B | $1.41B | $1.40B | $1.39B | |
| Retained Earnings | $-2.02B | $-1.97B | $-1.77B | $-1.59B | $-1.49B | $-1.40B | $-1.34B | $-1.47B | $-1.37B | $-1.25B | $-1.11B | $-1.10B | |
| Treasury Stock | $5M | $5M | $3M | $2M | $8M | $5M | $4M | $3M | $2M | $3M | $3M | $2M | |
| AOCI | $30.0K | $119.0K | $31.0K | $-428.0K | $-10.0K | $-6.0K | $84.0K | $-12.0K | $-222.0K | $-195.0K | $-219.0K | $-63.0K | |
| Stockholders' Equity | $108M | $146M | $93M | $117M | $114M | $156M | $117M | $-26M | $68M | $168M | $286M | $284M | |
| Liabilities + Equity | $185M | $298M | $229M | $194M | $137M | $204M | $418M | $284M | $437M | $476M | $652M | $471M | |
| Shares Outstanding | 365,848,216 | 363,020,303 | · | 189,214,000 | 150,082,000 | 142,289,000 | 106,679,000 | 106,162,000 | 105,711,000 | 104,582,000 | 103,860,000 | 103,663,000 |
नकदी प्रवाह 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $621.0K | $534.0K | $554.0K | $427.0K | $292.0K | $3M | $4M | $4M | $3M | $2M | $727.0K | $2M | |
| Stock-based Comp | $13M | $13M | $14M | $12M | $11M | $13M | $14M | $12M | $9M | $7M | $7M | $7M | |
| Deferred Tax | · | · | · | $0 | $0 | $0 | $-6M | $0 | $-13M | $0 | $0 | $-70.0K | |
| Amort. of Intangibles | · | · | · | · | · | · | · | $2M | $2M | · | · | · | |
| Other Non-cash | $-31M | $8M | $328.0K | $1M | $-10M | $-101M | $-28M | $-43M | $-57M | $-44M | · | $16M | |
| Operating Cash Flow | $-68M | $-179M | $-162M | $-89M | $-87M | $-143M | $114M | $-149M | $-185M | $-176M | $185M | $-76M | |
| CapEx | $0 | $1M | $470.0K | $1M | $1M | $87.0K | $70.0K | $95.0K | $228.0K | $231.0K | $910.0K | $80.0K | |
| Investing Cash Flow | $113M | $-15M | $-50M | $-71M | $2M | $381M | $-156M | $170M | $51M | $18M | $-117M | $-108M | |
| Debt Issued | $0 | $0 | $50M | $49M | · | $0 | $0 | $13M | $146M | $0 | $0 | $84M | |
| Net Debt Issued | $0 | $0 | · | $49M | $-12M | $-217M | $-1M | $-2M | $144M | $-2M | · | $82M | |
| Stock Issued | $0 | $0 | $139M | $94M | $37M | $70M | $0 | $732.0K | $8M | $4M | $114.0K | $202M | |
| Stock Repurchased | · | $2M | $824.0K | $864.0K | $3M | $1M | $941.0K | $972.0K | $2M | $621.0K | $357.0K | $887.0K | |
| Net Stock Activity | $0 | $-2M | $138M | $93M | $34M | $69M | $-941.0K | $-240.0K | $6M | $3M | · | $201M | |
| Financing Cash Flow | $-48M | $238M | $188M | $142M | $23M | $-148M | $-2M | $-2M | $150M | $987.0K | $-2M | $284M | |
| Net Change in Cash | $-3M | $44M | $-24M | $-18M | $-62M | $90M | $-44M | $19M | $15M | $-156M | $66M | $100M | |
| Free Cash Flow | $-68M | $-180M | $-162M | $-90M | $-88M | $-143M | $114M | $-149M | $-186M | $-176M | · | $-76M | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-182M | · | $-78M |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% | -199.2% | 43.9% | -163.4% | -151.3% | -164.6% | · | -439.2% | |
| Net Margin | -101.1% | -644.8% | -14710.9% | -73341.0% | -29449.0% | -244.1% | 40.4% | -190.7% | -142.9% | -169.7% | · | -438.8% | |
| Pretax Margin | · | · | · | · | -29449.0% | -244.1% | 38.5% | -190.7% | -156.9% | -169.7% | · | -439.1% | |
| EBITDA Margin | -97.0% | -632.5% | -14218.9% | -72182.0% | -29126.9% | -187.0% | 45.1% | -157.6% | -147.5% | -162.1% | · | -430.7% | |
| ROA | -20.8% | -75.9% | -83.6% | -61.6% | -51.5% | -18.9% | 37.1% | -33.5% | -28.3% | -25.1% | · | -26.9% | |
| ROE | -39.7% | -167.7% | -168.5% | -88.4% | -65.0% | -42.8% | 287.0% | -576.0% | -117.5% | -63.8% | · | -44.2% | |
| ROIC | · | · | · | · | · | · | · | · | · | -53.0% | · | -25.6% |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 | 3.4 | 5.2 | 4.7 | 2.6 | 2.2 | · | 8.2 | |
| Quick Ratio | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 | 3.3 | 5.0 | 4.5 | 2.5 | 2.2 | · | 7.6 | |
| Debt / Equity | 0.5 | 0.7 | 1.1 | · | 0.0 | 0.1 | 2.1 | -9.3 | 4.7 | 0.6 | · | 0.4 | |
| LT Debt / Equity | 0.5 | 0.7 | 1.1 | · | · | 0.0 | 2.0 | -9.2 | 4.4 | 0.5 | · | 0.3 | |
| Interest Coverage | · | · | · | -36.2 | -108.6 | -3.3 | 6.8 | -5.0 | -19.6 | -20.9 | · | -44.5 |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.1 | 0.9 | 0.2 | 0.2 | 0.1 | · | 0.1 | |
| Inventory Turnover | 1.1 | 2.0 | 0.4 | · | · | 0.9 | 0.7 | 0.8 | 1.9 | · | · | · | |
| Receivables Turnover | 17.0 | 13.9 | 2.3 | 6.6 | 1.5 | 0.8 | 10.3 | 11.8 | 14.7 | 19.8 | · | 25.0 |
विकास दरें 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 60.2% | 2481.5% | 766.2% | -53.4% | -98.8% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 610.2% | 370.7% | -63.1% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 15.7% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 14
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $50M | $31M | $1M | $139.0K | $298.0K | $24M | $322M | $63M | $92M | $79M | $130M | $23M | |
| Net Income TTM | $-50M | $-200M | $-177M | $-102M | $-88M | $-59M | $130M | $-121M | $-123M | $-131M | $-5M | $-100M | |
| Market Cap | $421M | · | · | $361M | $591M | $487M | $443M | $705M | $1.04B | $1.45B | · | $4.62B | |
| Enterprise Value | $378M | · | · | · | $505M | $346M | $416M | $790M | $979M | $1.20B | · | $4.39B | |
| P/E | -8.2 | -1.2 | -1.9 | -3.1 | -6.6 | -6.5 | 3.6 | -5.8 | -8.4 | -115.2 | -110.9 | · | |
| P/S | 8.4 | · | · | 2600.0 | 1984.3 | 20.3 | 1.4 | 11.2 | 11.4 | 18.2 | · | 202.3 | |
| P/B | 3.9 | · | · | 3.1 | 5.2 | 3.1 | 3.8 | -26.7 | 20.0 | 9.2 | · | 16.3 | |
| P / Tangible Book | 6.7 | · | · | 5.0 | 8.6 | 4.4 | · | · | · | · | · | · | |
| P / Cash Flow | -6.2 | · | · | -4.1 | -6.8 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| P / FCF | -6.2 | · | · | -4.0 | -6.7 | -3.4 | 3.9 | -4.7 | -5.6 | -8.2 | · | -61.1 | |
| EV / EBITDA | -7.8 | · | · | · | -5.8 | -7.7 | 2.9 | -7.9 | -7.3 | -8.9 | · | -44.6 | |
| EV / FCF | -5.6 | · | · | · | -5.7 | -2.4 | 3.7 | -5.3 | -5.3 | -6.8 | · | -58.0 | |
| EV / Revenue | 7.6 | · | · | · | 1693.2 | 14.4 | 1.3 | 12.5 | 10.7 | 15.2 | · | 192.1 | |
| Earnings Yield | -12.2% | -85.1% | -52.3% | -32.5% | -15.2% | -15.5% | 28.0% | -17.2% | -11.8% | -0.87% | -0.90% | · |
आय विवरण 14
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $692.0K | $21M | $5M | $14M | $29M | $1M | $27M | $2M | $2M | $1M | $701.0K | $162.0K | $317.0K | $24.0K | $28.0K | $39.0K | |
| Cost of Revenue | $39.0K | $108.0K | $201.0K | $10.0K | $33.0K | $30.0K | $348.0K | $71.0K | $166.0K | $31.0K | $70.0K | $7.0K | $8.0K | $0 | $0 | $0 | |
| R&D Expense | $17M | $13M | $11M | $19M | $16M | $15M | $27M | $26M | $18M | $14M | $15M | $18M | $15M | $12M | $14M | $11M | |
| SG&A Expense | $10M | $9M | $9M | $8M | $9M | $12M | $32M | $40M | $39M | $32M | $33M | $32M | $30M | $19M | $16M | $13M | |
| Operating Expenses | $27M | $22M | $20M | $26M | $25M | $27M | $59M | $65M | $57M | $46M | $47M | $50M | $45M | $31M | $30M | $23M | |
| Operating Income | $-27M | $-996.0K | $-15M | $-12M | $4M | $-26M | $-33M | $-64M | $-55M | $-45M | $-47M | $-50M | $-44M | $-31M | $-30M | $-23M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | · | · | $4M | $2M | $2M | · | $864.0K | |
| Other Non-op | $2M | $2M | $1M | $2M | $2M | $2M | $3M | $3M | $4M | $2M | $2M | $3M | $1M | $1M | $887.0K | $572.0K | |
| Net Income | $-32M | $-1M | $-16M | $-13M | $3M | $-25M | $-34M | $-65M | $-53M | $-48M | $-50M | $-51M | $-45M | $-32M | $-30M | $-23M | |
| EPS (Basic) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| EPS (Diluted) | $-0.07 | $0.00 | $-0.04 | $-0.04 | $0.01 | $-0.07 | $-0.08 | $-0.18 | $-0.17 | $-0.20 | $-0.20 | $-0.21 | $-0.22 | $-0.17 | $-0.17 | $-0.13 | |
| Shares (Basic) | 437,653,000 | 400,240,000 | -725,713,000 | 363,399,000 | 363,294,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | -307,937,000 | 174,904,000 | |
| Shares (Diluted) | 437,653,000 | 400,240,000 | -725,989,000 | 363,399,000 | 363,570,000 | 362,073,000 | -597,687,000 | 361,492,000 | 310,836,000 | 245,390,000 | -417,592,000 | 244,925,000 | 204,783,000 | 189,014,000 | 7,749,000 | 174,904,000 | |
| EBITDA | $-27M | $-886.0K | · | $-12M | $4M | $-26M | · | $-64M | $-55M | $-45M | · | $-50M | $-44M | $-31M | · | $-23M |
बैलेंस शीट 28
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $41M | $38M | $34M | $50M | $21M | $63M | $67M | $35M | $36M | $96M | · | $21M | $102M | $26M | · | $19M | |
| Short-term Investments | $150M | $133M | $62M | $66M | $118M | $132M | $171M | $224M | $274M | $259M | · | $197M | $154M | $80M | · | $117M | |
| Receivables | $2M | $12M | $2M | $2M | $2M | $47M | $3M | $3M | $3M | $2M | · | $318.0K | $685.0K | $261.0K | · | $39.0K | |
| Inventory | $1M | $276.0K | $281.0K | $158.0K | $168.0K | $201.0K | $231.0K | $636.0K | $585.0K | $514.0K | · | $336.0K | $172.0K | · | · | · | |
| Other Current Assets | $3M | $3M | $3M | $4M | $4M | $3M | $5M | $7M | $8M | $7M | · | $4M | $6M | $3M | · | $3M | |
| Current Assets | $197M | $186M | $102M | $123M | $145M | $246M | $246M | $269M | $321M | $365M | · | $223M | $264M | $110M | · | $139M | |
| PP&E (Net) | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $932.0K | |
| PP&E (Gross) | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $5M | · | $4M | $4M | $4M | · | $5M | |
| Goodwill | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | $45M | · | $45M | $45M | $45M | · | $45M | |
| Other Non-current Assets | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $368.0K | $828.0K | $828.0K | $828.0K | · | $743.0K | $6M | $6M | · | $7M | |
| Total Assets | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Accounts Payable | $2M | $3M | $3M | $4M | $6M | $11M | $15M | $14M | $12M | $8M | · | $12M | $11M | $10M | · | $9M | |
| Accrued Liabilities | $12M | $7M | $13M | $14M | $11M | $13M | $30M | $22M | $16M | $15M | · | $20M | $16M | $10M | · | $9M | |
| Current Liabilities | $15M | $10M | $21M | $22M | $35M | $111M | $45M | $36M | $28M | $23M | · | $32M | $26M | $20M | · | $18M | |
| Capital Leases | $6M | $6M | $7M | $7M | $4M | $4M | $5M | $5M | $5M | $5M | · | $5M | · | · | · | · | |
| Other Non-current Liabilities | $9M | $6M | $7M | $8M | $5M | $5M | $7M | $7M | $6M | · | · | · | $5M | $5M | · | $5M | |
| Total Liabilities | $76M | $66M | $77M | $86M | $96M | $175M | $152M | $143M | $133M | $128M | · | $137M | $130M | $75M | · | $48M | |
| Long-term Debt | $51M | $50M | $54M | · | · | $101M | $100M | · | · | · | · | $99M | $99M | $49M | · | $24M | |
| Total Debt | $51M | $50M | · | $57M | $56M | $101M | · | $100M | $99M | $100M | · | $99M | $99M | $49M | · | $24M | |
| Common Stock | $447.0K | $426.0K | $366.0K | $366.0K | $366.0K | $366.0K | $363.0K | $363.0K | $363.0K | $248.0K | · | $245.0K | $245.0K | $190.0K | · | $189.0K | |
| Paid-in Capital | $2.23B | $2.22B | $2.13B | $2.13B | $2.12B | $2.12B | $2.12B | $2.12B | $2.11B | $2.11B | · | $1.86B | $1.86B | $1.71B | · | $1.71B | |
| Retained Earnings | $-2.05B | $-2.02B | $-2.02B | $-2.00B | $-1.99B | $-1.99B | $-1.97B | $-1.93B | $-1.87B | $-1.82B | · | $-1.72B | $-1.67B | $-1.62B | · | $-1.56B | |
| Treasury Stock | $3M | $3M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | · | $3M | $3M | $3M | · | $2M | |
| AOCI | $-204.0K | $-130.0K | $30.0K | $29.0K | $-14.0K | $25.0K | $119.0K | $349.0K | $-193.0K | $-50.0K | · | $-113.0K | $-100.0K | $-163.0K | · | $-491.0K | |
| Stockholders' Equity | $175M | $203M | $108M | $120M | $129M | $123M | $146M | $179M | $240M | $289M | · | $140M | $186M | $88M | · | $144M | |
| Liabilities + Equity | $250M | $269M | $185M | $206M | $226M | $298M | $298M | $321M | $373M | $417M | · | $276M | $317M | $163M | · | $192M | |
| Shares Outstanding | 446,870,629 | 425,708,402 | 365,848,216 | 365,780,799 | · | · | 363,020,303 | · | · | · | · | · | · | · | · | · |
नकदी प्रवाह 14
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $102.0K | $110.0K | $118.0K | $151.0K | $176.0K | $176.0K | $125.0K | $126.0K | $139.0K | $144.0K | $147.0K | $151.0K | $144.0K | $112.0K | $103.0K | $108.0K | |
| Stock-based Comp | $3M | $3M | $3M | $3M | $3M | $3M | $2M | $3M | $5M | $4M | $3M | $4M | $4M | $3M | $3M | $3M | |
| Other Non-cash | · | $-17M | · | · | · | $-22M | · | · | · | $-11M | · | · | · | $-3M | · | · | |
| Operating Cash Flow | $-9M | $-15M | $-17M | $-24M | $17M | $-44M | $-21M | $-54M | $-49M | $-55M | $-51M | $-42M | $-38M | $-32M | $-22M | $-19M | |
| CapEx | · | · | $0 | $0 | · | · | $474.0K | $307.0K | $250.0K | $0 | $0 | $83.0K | $139.0K | $248.0K | $1M | $4.0K | |
| Investing Cash Flow | $-16M | $-70M | $5M | $52M | $15M | $41M | $54M | $53M | $-12M | $-110M | $52M | $-39M | $-75M | $12M | $24M | $-77M | |
| Debt Issued | · | · | · | · | · | · | $0 | $0 | · | · | $-1.0K | $1.0K | $50M | $0 | $25M | $-249.0K | |
| Net Debt Issued | · | · | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | |
| Stock Issued | $791.0K | $70M | · | · | $0 | $0 | $0 | $0 | $-88.0K | $88.0K | $0 | $-211.0K | $139M | $0 | $-63.0K | $94M | |
| Stock Repurchased | · | · | · | · | · | · | · | $0 | $0 | $2M | · | $0 | $0 | $824.0K | $0 | $0 | |
| Net Stock Activity | · | $70M | · | · | · | · | · | · | · | $-2M | · | · | · | $-824.0K | · | · | |
| Financing Cash Flow | $-512.0K | $89M | $-3M | $0 | $-45M | $-572.0K | $-104.0K | $-916.0K | $-14.0K | $239M | $-1.0K | $-210.0K | $189M | $-824.0K | $25M | $94M | |
| Net Change in Cash | $-26M | $4M | $-15M | $28M | $-13M | $-4M | $32M | $-1M | $-61M | $74M | $1M | $-81M | $76M | $-20M | $28M | $-3M | |
| Free Cash Flow | · | · | · | · | · | · | · | · | · | $-55M | · | · | · | $-32M | · | · |
लाभप्रदता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -3835.3% | -4.7% | · | -85.9% | 12.9% | -2034.8% | · | -3639.6% | -3360.9% | -4011.8% | · | -30636.4% | -13955.8% | · | · | · | |
| Net Margin | -4591.8% | -4.9% | · | -90.0% | 11.3% | -2004.4% | · | -3703.5% | -3244.0% | -4282.9% | · | -31188.3% | -14165.3% | · | · | · | |
| EBITDA Margin | -3835.3% | -4.2% | · | -85.9% | 12.9% | -2020.8% | · | -3639.6% | -3360.9% | -3999.0% | · | -30636.4% | -13955.8% | · | · | · | |
| ROA | -13.4% | -0.37% | · | -4.9% | 1.1% | -7.1% | · | -21.7% | -15.5% | -16.7% | · | -21.6% | -20.9% | -21.4% | · | -12.8% | |
| ROE | -20.9% | -0.64% | · | -8.6% | 1.8% | -12.3% | · | -40.8% | -25.1% | -25.7% | · | -35.6% | -34.9% | -35.3% | · | -16.7% |
तरलता और शोधन क्षमता 5
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 13.4 | 18.8 | · | 5.6 | 4.2 | 2.2 | · | 7.5 | 11.5 | 15.6 | · | 6.9 | 10.1 | 5.4 | · | 7.5 | |
| Quick Ratio | 13.1 | 18.4 | · | 5.4 | 4.1 | 2.2 | · | 7.2 | 11.2 | 15.3 | · | 6.8 | 9.9 | 5.2 | · | 7.4 | |
| Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.8 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| LT Debt / Equity | 0.3 | 0.2 | · | 0.5 | 0.4 | 0.5 | · | 0.6 | 0.4 | 0.3 | · | 0.7 | 0.5 | 0.6 | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | · | · | -12.7 | -22.6 | -17.1 | · | -26.7 |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.1 | · | 0.1 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Inventory Turnover | 0.1 | 0.5 | · | 0.0 | 0.1 | 0.1 | · | 0.1 | 0.4 | 0.0 | · | 0.0 | 0.0 | · | · | · | |
| Receivables Turnover | 0.4 | 0.7 | · | 5.4 | 12.0 | 0.1 | · | 1.1 | 1.0 | 1.3 | · | 0.9 | 0.9 | · | · | · |
मूल्यांकन (TTM) 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $65M | $65M | · | $46M | $34M | $6M | · | $5M | $3M | $2M | · | $542.0K | $415.0K | · | · | · | |
| Net Income TTM | $-42M | $-36M | · | $-100M | $-140M | $-192M | · | $-217M | $-197M | $-176M | · | $-151M | $-125M | $-103M | · | $-95M | |
| Market Cap | $1.07B | $664M | · | $494M | · | · | · | · | · | · | · | · | · | · | · | · | |
| Enterprise Value | $933M | $543M | · | $434M | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/E | -24.0 | -15.6 | · | -4.8 | -2.3 | -0.7 | · | -2.1 | -2.1 | -3.0 | · | -1.5 | · | · | · | · | |
| P/S | 16.5 | 10.2 | · | 10.7 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P/B | 6.1 | 3.3 | · | 4.1 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Tangible Book | 8.3 | 4.2 | · | 6.5 | · | · | · | · | · | · | · | · | · | · | · | · | |
| P / Cash Flow | · | -45.1 | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / EBITDA | -35.2 | -613.0 | · | -35.6 | · | · | · | · | · | · | · | · | · | · | · | · | |
| EV / Revenue | 14.4 | 8.3 | · | 9.4 | · | · | · | · | · | · | · | · | · | · | · | · | |
| Earnings Yield | -4.2% | -6.4% | · | -20.7% | -43.2% | -134.8% | · | -48.4% | -47.6% | -33.3% | · | -67.0% | · | · | · | · |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $50M | $31M | $1M | $139.0K | $298.0K |
| परिचालन मार्जिन % | -98.2% | -634.2% | -14264.9% | -72489.2% | -29224.8% |
| शुद्ध आय | $-50M | $-200M | $-177M | $-102M | $-88M |
| तनुकरणित EPS | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.5 | 0.7 | 1.1 | — | 0.0 |
| वर्तमान अनुपात | 4.9 | 5.4 | 5.6 | 6.1 | 4.0 |
| त्वरित अनुपात | 4.7 | 5.3 | 5.4 | 6.0 | 3.9 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $-68M | $-180M | $-162M | $-90M | $-88M |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
📊
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 169 फाइलर्स · $760.9M कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 48 (+14 पिछली तिमाही की तुलना में) | 27 (+14 पिछली तिमाही की तुलना में) | 34 (-11 पिछली तिमाही की तुलना में) | 37 (+17 पिछली तिमाही की तुलना में) | +25.0M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| Artal Group S.A. | $420374549 | 175156062 | 55.25% | शेयर |
| Siren, L.L.C. | $106328443 | 44303518 | 13.97% | शेयर |
| FMR LLC | $65057059 | 27107108 | 8.55% | शेयर |
| Sessa Capital IM, L.P. | $45506006 | 18960836 | 5.98% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $23762899 | 9901208 | 3.12% | शेयर |
| Point72 Asset Management, L.P. | $19803180 | 8251325 | 2.60% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $12946507 | 5393025 | 1.70% | शेयर |
| STATE STREET CORP | $11802646 | 4917769 | 1.55% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $5658598 | 2357749 | 0.74% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4696260 | 1956775 | 0.62% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $3922970 | 1634571 | 0.52% | शेयर |
| CIBC Private Wealth Group LLC | $3240347 | 2400257 | 0.43% | शेयर |
| Ishara Investments LP | $3050400 | 1271000 | 0.40% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $2722150 | 1134229 | 0.36% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $2704800 | 1127000 | 0.36% | शेयर |
| MACKENZIE FINANCIAL CORP | $2312050 | 963354 | 0.30% | शेयर |
| ADAR1 Capital Management, LLC | $1800000 | 750000 | 0.24% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1604400 | 668500 | 0.21% | कॉल ऑप्शन |
| TWO SIGMA INVESTMENTS, LP | $1544266 | 643444 | 0.20% | शेयर |
| JANE STREET GROUP, LLC | $1398960 | 582900 | 0.18% | कॉल ऑप्शन |
| CITADEL ADVISORS LLC | $1348733 | 561972 | 0.18% | शेयर |
| VANGUARD GROUP INC | $1277587 | 1110945 | 0.17% | शेयर |
| Compagnie Lombard Odier SCmA | $1152000 | 480000 | 0.15% | शेयर |
| BARCLAYS PLC | $890636 | 371098 | 0.12% | शेयर |
| CITADEL ADVISORS LLC | $886320 | 369300 | 0.12% | कॉल ऑप्शन |
| XTX Topco Ltd | $858905 | 357877 | 0.11% | शेयर |
| GOLDMAN SACHS GROUP INC | $725810 | 302421 | 0.10% | शेयर |
| CANADA PENSION PLAN INVESTMENT BOARD | $618960 | 257900 | 0.08% | शेयर |
| RHUMBLINE ADVISERS | $616523 | 256885 | 0.08% | शेयर |
| WELLS FARGO & COMPANY/MN | $544865 | 227027 | 0.07% | शेयर |
| GROUP ONE TRADING LLC | $420031 | 175013 | 0.06% | शेयर |
| Virtus Investment Advisers, LLC | $408996 | 170415 | 0.05% | शेयर |
| Headlands Technologies LLC | $401275 | 167198 | 0.05% | शेयर |
| Ikarian Capital, LLC | $395218 | 164674 | 0.05% | शेयर |
| CITIGROUP INC | $386021 | 160842 | 0.05% | शेयर |
| Quarry LP | $374846 | 156186 | 0.05% | शेयर |
| MetLife Investment Management, LLC | $351384 | 146410 | 0.05% | शेयर |
| Bank of New York Mellon Corp | $345307 | 143878 | 0.05% | शेयर |
| BANK OF AMERICA CORP /DE/ | $344321 | 143467 | 0.05% | शेयर |
| PANAGORA ASSET MANAGEMENT INC | $316901 | 132042 | 0.04% | शेयर |
| State of Wyoming | $285816 | 119090 | 0.04% | शेयर |
| BlackRock, Inc. | $284436 | 118515 | 0.04% | शेयर |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $273874 | 114114 | 0.04% | शेयर |
| Cornerstone Investment Partners, LLC | $272974 | 113739 | 0.04% | शेयर |
| Invesco Ltd. | $238190 | 99246 | 0.03% | शेयर |
| ALGERT GLOBAL LLC | $221160 | 92150 | 0.03% | शेयर |
| TWO SIGMA ADVISERS, LP | $208124 | 180977 | 0.03% | शेयर |
| BANK OF NOVA SCOTIA | $207857 | 86607 | 0.03% | शेयर |
| LPL Financial LLC | $203799 | 84916 | 0.03% | शेयर |
| Vanguard Global Advisers, LLC | $187070 | 77946 | 0.02% | शेयर |
| AQR CAPITAL MANAGEMENT LLC | $180101 | 75042 | 0.02% | शेयर |
| Police & Firemen's Retirement System of New Jersey | $176165 | 73402 | 0.02% | शेयर |
| UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | $171426 | 71427 | 0.02% | शेयर |
| PRUDENTIAL FINANCIAL INC | $171228 | 71345 | 0.02% | शेयर |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $167393 | 69747 | 0.02% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $164160 | 68400 | 0.02% | शेयर |
| TWO SIGMA SECURITIES, LLC | $159300 | 66375 | 0.02% | शेयर |
| SEI INVESTMENTS CO | $153449 | 63937 | 0.02% | शेयर |
| Nuveen, LLC | $153449 | 63937 | 0.02% | शेयर |
| Straight Path Wealth Management | $150398 | 62666 | 0.02% | शेयर |
| WELLINGTON MANAGEMENT GROUP LLP | $144000 | 60000 | 0.02% | शेयर |
| R Squared Ltd | $131964 | 54985 | 0.02% | शेयर |
| Vanguard Personalized Indexing Management, LLC | $130402 | 54334 | 0.02% | शेयर |
| Fortis Group Advisors, LLC | $120000 | 50000 | 0.02% | शेयर |
| Schonfeld Strategic Advisors LLC | $118642 | 49435 | 0.02% | शेयर |
| SCOTIA CAPITAL INC. | $117291 | 48871 | 0.02% | शेयर |
| PROFUND ADVISORS LLC | $116606 | 48586 | 0.02% | शेयर |
| VOYA INVESTMENT MANAGEMENT LLC | $114650 | 47771 | 0.02% | शेयर |
| AXQ CAPITAL, LP | $109745 | 45727 | 0.01% | शेयर |
| BOOTHBAY FUND MANAGEMENT, LLC | $106356 | 44315 | 0.01% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $105768 | 67800 | 0.01% | शेयर |
| WINTON GROUP Ltd | $103680 | 43200 | 0.01% | शेयर |
| INTECH INVESTMENT MANAGEMENT LLC | $101978 | 42491 | 0.01% | शेयर |
| LMR Partners LLP | $98618 | 41091 | 0.01% | शेयर |
| BANK OF MONTREAL /CAN/ | $96000 | 40000 | 0.01% | शेयर |
| NORTHERN TRUST CORP | $93794 | 39081 | 0.01% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $90672 | 37780 | 0.01% | शेयर |
| Cubist Systematic Strategies, LLC | $85704 | 63484 | 0.01% | शेयर |
| Rafferty Asset Management, LLC | $81816 | 34090 | 0.01% | शेयर |
| ProShare Advisors LLC | $78212 | 32588 | 0.01% | शेयर |
| Leonteq Securities AG | $72000 | 30000 | 0.01% | शेयर |
| PINNACLE ASSOCIATES LTD | $69636 | 29015 | 0.01% | शेयर |
| VICTORY CAPITAL MANAGEMENT INC | $58135 | 24223 | 0.01% | शेयर |
| Legal & General Group Plc | $58044 | 24185 | 0.01% | शेयर |
| XPONANCE LLC | $57031 | 23763 | 0.01% | शेयर |
| Graham Capital Management, L.P. | $56498 | 23541 | 0.01% | शेयर |
| D. E. Shaw & Co., Inc. | $53280 | 22200 | 0.01% | शेयर |
| Quadrature Capital Ltd | $52795 | 21998 | 0.01% | शेयर |
| Invera Wealth Advisors, LLC | $48000 | 20000 | 0.01% | शेयर |
| DIKER MANAGEMENT LLC | $48000 | 20000 | 0.01% | शेयर |
| TIAA-CREF INDIVIDUAL & INSTITUTIONAL SERVICES, LLC | $48000 | 20000 | 0.01% | शेयर |
| Russell Investments Group, Ltd. | $47764 | 19902 | 0.01% | शेयर |
| Point72 Asia (Singapore) Pte. Ltd. | $47282 | 35024 | 0.01% | शेयर |
| Tower Research Capital LLC (TRC) | $46764 | 19485 | 0.01% | शेयर |
| KWB Wealth | $46736 | 40640 | 0.01% | शेयर |
| SBI Securities Co., Ltd. | $46092 | 19205 | 0.01% | शेयर |
| PRINCIPAL FINANCIAL GROUP INC | $45682 | 19034 | 0.01% | शेयर |
| CREDIT AGRICOLE S A | $45540 | 18975 | 0.01% | शेयर |
| WOLVERINE TRADING, LLC | $43785 | 31500 | 0.01% | पुट ऑप्शन |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $42960 | 17900 | 0.01% | पुट ऑप्शन |
कंपनी के अंदरूनी सूत्र 49 इनसाइडर्स · 32 अधिकारी · 19 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Michael Exton | Chief Executive Officer | 28 फ़रवरी 2026 M | 298432 | 0 | 0 | $0 |
| Lonnel Coats | Chief Executive Officer | 28 फ़रवरी 2024 M | 1098068 | 0 | 0 | $0 |
| Arthur T Sands | President & CEO | 28 फ़रवरी 2014 M | 1021329 | 0 | 0 | $0 |
| Scott M Coiante | SVP, Chief Financial Officer | 28 फ़रवरी 2026 M | 105356 | 0 | 0 | $0 |
| Ajay Bansal | EVP Corp Dev and CFO | 2 जून 2009 A | — | 0 | 0 | $0 |
| Julia P Gregory | EVP and CFO | 7 फ़रवरी 2008 A | 50200 | 0 | 0 | $0 |
| Jeffrey L Wade | President and COO | 8 जुलाई 2024 A | 324214 | 0 | 0 | $0 |
| Rachel Yap Martens | SVP, Partnerships & Corp Strat | 28 फ़रवरी 2026 M | 31264 | 0 | 0 | $0 |
| Suma Gopinathan | SVP, Discovery | 28 फ़रवरी 2026 M | 150132 | 0 | 0 | $0 |
| Wendy Mcdermott | SVP, Human Resources | 28 फ़रवरी 2026 M | 277945 | 0 | 0 | $0 |
| Craig B Granowitz | SVP, Chief Medical Officer | 28 फ़रवरी 2026 M | 323430 | 0 | 0 | $0 |
| Lisa Defrancesco | SVP, IR and Corp Comm | 28 फ़रवरी 2026 M | 93869 | 0 | 0 | $0 |
| Brian T Crum | SVP, General Counsel & Secr. | 28 फ़रवरी 2026 M | 428802 | 0 | 0 | $0 |
| Kristen Alexander | VP, Finance and Accounting | 28 फ़रवरी 2025 M | 76368 | 0 | 0 | $0 |
| Alan J Main | EVP, Innov & Chem Sciences | 28 फ़रवरी 2025 M | 339104 | 0 | 0 | $0 |
| Brian Corrigan | SVP, Regulatory & QA | 13 फ़रवरी 2025 A | — | 0 | 0 | $0 |
| Kenneth B. Kassler-Taub | SVP, Regulatory & QA | 28 फ़रवरी 2024 M | 162672 | 0 | 0 | $0 |
| Thomas Garner | SVP, Chief Commercial Officer | 8 फ़रवरी 2024 A | — | 0 | 0 | $0 |
| Kiernan Seth | VP, Chief Commercial Officer | 28 फ़रवरी 2023 M | 53136 | 0 | 0 | $0 |
| James F Tessmer | VP, Finance & Accounting | 15 मार्च 2021 M | 71766 | 0 | 0 | $0 |
| Alexander A Santini | EVP and CCO | 22 अप्रैल 2020 F | 55584 | 0 | 0 | $0 |
| Pablo Lapuerta | EVP and CMO | 22 अप्रैल 2020 F | 85719 | 0 | 0 | $0 |
| John Northcott | VP, Marketing, Comm Strategy | 2 मार्च 2015 M | 8235 | 0 | 0 | $0 |
| Brian P Zambrowicz | EVP, Chief Scientific Officer | 28 फ़रवरी 2014 M | 278703 | 0 | 0 | $0 |
| Steven Alan Tragash | VP, Corporate Affairs | 15 फ़रवरी 2010 A | — | 0 | 0 | $0 |
| Philip M Brown | SVP, Clinical Development | 15 फ़रवरी 2010 A | 27306 | 0 | 0 | $0 |
| James R Piggott PHD | SVP of Pharm Bio | 7 फ़रवरी 2008 A | 0 | 0 | 0 | $0 |
| Lance K Ishimoto | SVP, Intellectual Property | 7 फ़रवरी 2008 A | 10200 | 0 | 0 | $0 |
| Tamar D Howson | EVP of Bus Dev | 7 फ़रवरी 2008 A | — | 0 | 0 | $0 |
| Walter F Colbert | SVP, HR and Corp Serv | 13 फ़रवरी 2007 A | — | 0 | 0 | $0 |
| Randall B Riggs | SVP, Corp Licensing | 23 फ़रवरी 2004 M | 15000 | 0 | 0 | $0 |
| Christophe Person | VP Informatics | 12 जनवरी 2004 M | 0 | 0 | 0 | $0 |
| Ivan Cheung | निदेशक | 3 जून 2026 M | 89312 | 0 | 0 | $0 |
| Diane E. Sullivan | निदेशक | 3 जून 2026 M | 126122 | 0 | 0 | $0 |
| Judith L Swain | निदेशक | 3 जून 2026 M | 174486 | 0 | 0 | $0 |
| Amouyal Philippe | निदेशक | 3 जून 2026 M | 374486 | 0 | 0 | $0 |
| Sam L Barker | निदेशक | 3 जून 2026 M | 213771 | 0 | 0 | $0 |
| Christopher J Sobecki | निदेशक | 3 जून 2026 M | 293177 | 0 | 0 | $0 |
| Raymond Debbane | निदेशक | 3 जून 2026 M | 1995498 | 7 | 0 | $723048 |
| Robert J Lefkowitz MD | निदेशक | 13 मई 2024 A | 48364 | 0 | 0 | $0 |
| Frank Palantoni | निदेशक | 21 मई 2023 M | 40332 | 0 | 0 | $0 |
| Alan S Nies | निदेशक | 21 मई 2023 M | 41046 | 0 | 0 | $0 |
| Invus C.V. | निदेशक | 31 दिसमबर 2020 J | 0 | 0 | 0 | $0 |
| Kathleen M Wiltsey | निदेशक | 24 अप्रैल 2009 A | — | 0 | 0 | $0 |
| Clayton Stuart Rose | निदेशक | 26 जून 2007 P | 25000 | 0 | 0 | $0 |
| Barry Mills | निदेशक | 26 अप्रैल 2007 A | 25000 | 0 | 0 | $0 |
| Patricia M Cloherty | निदेशक | 27 अप्रैल 2006 A | — | 0 | 0 | $0 |
| Thomas C Caskey | निदेशक | 13 अक्टूबर 2005 P | 6300 | 0 | 0 | $0 |
| Praveen Tyle | — | 28 फ़रवरी 2021 M | 120791 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 11 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Invus, L.P., Invus Advisors, L.L.C., Invus Public Equities, L.P., Invus Public Equities Advisors, LLC, Invus Global Management, LLC, Siren, L.L.C., Avicenna Life Sci Master Fund LP, Avicenna Life Sci Master GP LLC, Invus US Partners LLC, Ulys, L.L.C., Raymond Debbane, Artal Participations S.a r.l., Artal International S.C.A., Artal International Management S.A., Artal Group S.A., Westend S.A., Stichting Administratiekantoor Westend, Amaury Wittouck ×7 फाइलिंग | 8 मई 2026 | 39.40% | संशोधन | — | SEC |
| Invus, L.P. (2), Invus Advisors, L.L.C. (2), Invus Public Equities, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Global Management, LLC (2), Siren, L.L.C. (2), Artal Participations S.à r.l. (2), Artal International S.C.A. (2), Artal International Management S.A. (2), Artal Group S.A. (2), Westend S.A. (2), Stichting Administratiekantoor Westend (2), Mr. Amaury Wittouck (2), Invus US Partners LLC (2), Ulys, L.L.C. (2), Mr. Raymond Debbane (2) ×15 फाइलिंग | 9 दिसमबर 2024 | — | प्रारंभिक फाइलिंग | — | SEC |
| 24 फ़रवरी 2012 | — | प्रारंभिक फाइलिंग | — | SEC | |
| Raymond Debbane (2), Ulys, L.L.C. (2), Invus Advisors, L.L.C. (2), Invus, L.P. (2), Invus Public Equities Advisors, LLC (2), Invus Public Equities, L.P. (2), Invus C.V. (2) | 27 दिसमबर 2011 | — | प्रारंभिक फाइलिंग | — | SEC |
| 14 नवमबर 2011 | — | प्रारंभिक फाइलिंग | — | SEC | |
| 15 अगस्त 2011 | — | प्रारंभिक फाइलिंग | — | SEC | |
| Raymond Debbane, Ulys, L.L.C., Invus Advisors, L.L.C., Invus, L.P., Invus Public Equities Advisors, LLC, Invus Public Equities, L.P., Invus C.V. | 19 मार्च 2010 | — | प्रारंभिक फाइलिंग | पूंजी संरचना | SEC |
| Estate of Gordon A. Cain (, Mary H. Cain ×4 फाइलिंग | 5 अगस्त 2005 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 8 अगस्त 2003 | — | प्रारंभिक फाइलिंग | — | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 18 जुलाई 2003 | — | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 19 मार्च 2003 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 14 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| SCHA · SCHWAB STRATEGIC TRUST | 0.01% | 1032223 NS | 31 मई 2026 | N-PORT |
| SCHB · SCHWAB STRATEGIC TRUST | 0.00% | 110085 NS | 31 मई 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTI · VANGUARD INDEX FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15 जुलाई 2026 | दैनिक |
| IWV · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWO · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWM · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| IWC · iShares Trust | — | — | 18 अगस्त 2026 | दैनिक |
| PRFZ · Invesco Exchange-Traded Fund Trust | — | — | 13 जुलाई 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | — | — | 20 जुलाई 2026 | दैनिक |
| QQQS · Invesco Exchange-Traded Fund Trust … | — | — | 5 अगस्त 2026 | दैनिक |